Stelara: The Beginning Of The End

J&J’s fourth-quarter and full-year results have confirmed the decline for Stelara that had already begun to be seen late last year. And with US biosimilars now set to take a slice of the ustekinumab market following the launch of multiple European rivals last year, for the originator the only way is down.